Suppressive antibiotic treatment (SAT) in the Era of MDRO infections: a narrative review DOI
Valentina Fornari,

Guido Accardo,

Tommaso Lupia

et al.

Expert Review of Anti-infective Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: Feb. 28, 2025

Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety efficacy in the short term; however, prolonged course of antibiotics has been documented multiple clinical settings. The aim this narrative review is provide a new perspective SAT discuss therapeuticpossibilities. We scenarios which could be considered. provided broad discussion about long-acting agents or repurposed oral as well use OPAT with elastomeric pumps an overview pipeline antifungals. Limitations are presented especially patients' adherence issues, possible spread MDROs, rising incidence Clostridioides difficile drug-to-drug interactions drug-related problems, cost-effectiveness evaluation issues. Many gaps evident further needed. Above all, different scenarios. Discovery molecules against MDROs ongoing PK/PD variables better understanding relationship between emergence resistance improve usage reduce impact DRPs.

Language: Английский

Suppressive antibiotic treatment (SAT) in the Era of MDRO infections: a narrative review DOI
Valentina Fornari,

Guido Accardo,

Tommaso Lupia

et al.

Expert Review of Anti-infective Therapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 13

Published: Feb. 28, 2025

Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety efficacy in the short term; however, prolonged course of antibiotics has been documented multiple clinical settings. The aim this narrative review is provide a new perspective SAT discuss therapeuticpossibilities. We scenarios which could be considered. provided broad discussion about long-acting agents or repurposed oral as well use OPAT with elastomeric pumps an overview pipeline antifungals. Limitations are presented especially patients' adherence issues, possible spread MDROs, rising incidence Clostridioides difficile drug-to-drug interactions drug-related problems, cost-effectiveness evaluation issues. Many gaps evident further needed. Above all, different scenarios. Discovery molecules against MDROs ongoing PK/PD variables better understanding relationship between emergence resistance improve usage reduce impact DRPs.

Language: Английский

Citations

0